View Older Stories View More Recent Stories

Jul 22, 2019 10:37PM Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA
Jun 25, 2019 08:00AM Eisai Presents Data To Assess Seizure Freedom With FYCOMPA® Monotherapy In Newly Diagnosed Or Untreated Patients With Partial Onset Seizures
Jun 13, 2019 08:05AM Eisai To Present FYCOMPA® Seizure FREEDOM Data In New Onset Patients And Pediatric Data At The 33rd International Epilepsy Congress
Jun 4, 2019 08:00AM Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
May 16, 2019 12:45PM Eisai Announces Data Presentations on Oncology Pipeline, including LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Investigational Combination Therapy at ASCO 2019
May 10, 2019 08:40AM Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease
May 9, 2019 01:17PM Lower Hospitalization Rates In Epilepsy Patients Treated With Adjunctive FYCOMPA® (perampanel) CIII
Mar 29, 2019 08:08AM Eisai Announces Presentations of Latest Research on Oncology Pipeline at the 110th American Association for Cancer Research (AACR) Annual Meeting
Feb 25, 2019 08:01AM FDA Accepts Eisai's Supplemental New Drug Application (sNDA) to Update the Labeling for Anti-Obesity Agent BELVIQ® (lorcaserin HCl)
Feb 20, 2019 11:50PM AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
Feb 19, 2019 10:05AM Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.
Feb 11, 2019 08:35AM METAvivor and Presenting Sponsor Eisai Inc. Join Forces with AnaOno Intimates to Bring to Life the #ThisIsMBC Elements Campaign through Fashion
Dec 5, 2018 07:24PM Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
Nov 28, 2018 08:35AM Eisai and METAvivor Team Up to Launch Elements as the Latest #ThisIsMBC Initiative at the 2018 San Antonio Breast Cancer Symposium
Oct 28, 2018 07:45PM Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD
Oct 25, 2018 06:03PM Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease
Oct 24, 2018 10:00AM Eisai and Oklahoma Health Care Authority Enter Value-Based Agreement for FYCOMPA
Oct 22, 2018 03:34AM Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan
Oct 17, 2018 07:30PM Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At The 11th Clinical Trials On Alzheimer's Disease (CTAD) Conference
Oct 16, 2018 08:08AM Eisai To Present New Research On Human Genetics And Drug Discovery At ASHG Conference 2018
Oct 4, 2018 07:30AM Eisai Announces New Data on the Effect of Anti-Obesity Agent BELVIQ® (lorcaserin HCl) on Prevention and Remission of Type 2 Diabetes Presented at the European Association for the Study of Diabetes (E
Sep 28, 2018 02:54PM Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures
Aug 27, 2018 11:56AM Eisai Announces Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ® Presented at the European Society of Cardiology and Published in the New England Journal of Medicine
Aug 17, 2018 08:00AM Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Aug 16, 2018 04:11PM Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Jul 30, 2018 09:27PM Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
Jul 18, 2018 08:00AM Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At Alzheimer's Association International Conference 2018
Jul 17, 2018 09:00AM Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®
Jul 9, 2018 10:20PM Eisai Announces Acceptance of BAN2401 Phase II Results for Oral Presentation at the 2018 Alzheimer's Association International Conference (AAIC)
Jun 12, 2018 04:30PM Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts
Jun 11, 2018 02:00PM Lihua Yu, Ph.D., Appointed President & Chief Data Sciences Officer, H3 Biomedicine
Jun 5, 2018 01:58PM Eisai, Biogen (BIIB) Report Phase II Study Of Elenbecestat Demonstrated Safety And Tolerability In MCI And Mild To Moderate AD At 18-Months
Jun 5, 2018 01:55PM Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months
Jun 3, 2018 06:00PM Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types
May 24, 2018 07:34PM Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
Apr 9, 2018 10:00AM Morphotek Announces Agreement to License its Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical Co., Ltd. for Development of a Therapeutic Antibody-Drug Conjugate (ADC)*
Mar 23, 2018 01:41AM AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
Jan 24, 2018 10:00AM Morphotek To Present Poster On CA125 Suppression Of Humoral Immune Responses Of Antibodies At The Upcoming ASCO-SITC Clinical Immuno-oncology Symposium
Jan 10, 2018 09:00AM Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Jan 9, 2018 06:45AM Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Ca
Jan 9, 2018 06:24AM Biogen and Eisai Commence Co-Promotion of Multiple Sclerosis Treatments in Japan
Dec 21, 2017 08:22PM Eisai: Adaptive Phase II Study of BAN2401 In Early Alzheimer's Disease Continues Toward 18-Month Endpoint
Dec 11, 2017 10:00AM Morphotek And Rockefeller University Form A Sponsored Research Agreement To Study The Immunosuppressive Effects Of The Tumor Shed Antigen CA125 And Its Potential Impact In Future Patient Therapies
Dec 7, 2017 10:00AM Morphotek To Present Its Proprietary RESPECT™ Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego
Dec 4, 2017 10:00AM Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression
Nov 13, 2017 03:00PM Morphotek To Present Its Proprietary RESPECT™ Antibody Drug Conjugate (ADC) Technology At The Upcoming 9th Annual PEGS Europe In Lisbon
Oct 3, 2017 08:00AM Eisai Inc. and Grupo Biotoscana Sign Exclusive Licensing Agreement for the Commercialization of Eisai's Oncology and Neurology Products throughout Latin America
Sep 19, 2017 10:00AM Morphotek To Present Preclinical Data On Antibody-Drug Conjugate MORAb-202 At The Upcoming 8th Annual World ADC In San Diego
Sep 6, 2017 10:00AM Morphotek Announces Collaboration Agreement With The Johns Hopkins University To Research And Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens
Sep 5, 2017 10:00AM Morphotek®, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab®
View More Recent Stories View Older Stories